Melanoma and immunotherapy bridge 2015

Andrew J. Park | A. Hauschild | J. Malvehy | L. Cope | H. Kohrt | J. Taube | C. Horak | Jinshui Fan | K. Flaherty | C. Croce | L. Fattore | R. Mancini | D. Malpicci | G. Madonna | D. Mallardo | G. Botti | P. Ascierto | G. Ciliberto | Hong Wang | R. Dummer | J. Wolchok | M. Cantile | M. Atkins | J. Sosman | C. Cheadle | C. Drake | Joe-Marc Chauvin | Ornella Pagliano | M. Vetizou | J. Kirkwood | H. Zarour | L. Zitvogel | G. Kroemer | A. Ribas | G. Liguori | L. Danilova | S. Costantini | A. Testori | G. Netto | S. Demaria | R. Amaria | P. Hwu | H. Schmidt | M. Sznol | P. Queirolo | C. Garbe | M. Mandalà | M. Guida | C. Slingluff | T. Crook | F. Sallusto | N. Rizvi | D. Kaufman | N. Segal | H. Kluger | M. Callahan | M. Postow | A. Lesokhin | M. Burke | S. Kronenberg | B. Agunwamba | A. Korman | Y. Shoenfeld | D. Pardoll | P. Berglund | S. Tommasi | J. Grob | L. Demidov | P. Rutkowski | P. Chapman | G. Scognamiglio | S. Scala | G. McArthur | G. Long | J. Haanen | M. Maio | D. Hogg | P. Lorigan | C. Lebbé | B. Dréno | R. Kiessling | A. Azzariti | O. Michielin | O. Csuka | J. Hansson | C. Proby | N. Syed | S. Ferrone | M. Maurer | M. Blank | C. McNeil | T. Andersson | S. Topalian | D. Stroncek | S. Formenti | Yibing Yan | T. Rau | M. L. Motti | S. Dalle | A. Santoni | S. Pepe | P. Michelozzi | D. Enot | C. Loquai | Adeeb H. Rahman | S. Gnjatic | M. Wongchenko | A. Jungbluth | A. Balmanoukian | R. Bono | F. Passarelli | A. Ianaro | A. Pessi | W. Peng | E. Panza | Haidong Tang | O. Hamid | M. Merlano | S. Cinca | J. Weber | M. Ballinger | M. Maio | G. Pirozzi | P. Quaglino | J. Luke | J. Cebon | J. Hassel | T. Gajewski | I. Sperduti | J. Baurain | F. Pagès | G. Cirino | C. Marino | O. Franzese | L. Mortier | F. Aubin | V. Hirsh | L. Leopold | P. Boasberg | L. Thomas | B. Weide | A. Marabelle | L. Aurisicchio | R. Anders | T. McMiller | Haiying Xu | M. Minopoli | K. Leandersson | A. Vanderwalde | J. Wasser | V. Umansky | Jianda Yuan | P. Wong | I. Márquez-Rodas | S. Hodi | L. de la Cruz-Merino | T. Yamazaki | L. Rivoltini | J. Pitt | R. Daillère | C. Flament | S. Rusakiewicz | M. Roberti | V. poirier-colame | N. Jacquelot | T. Gangadhar | V. Atkinson | G. Liszkay | C. Dutriaux | I. Chang | A. Lugli | S. Mastroeni | A. Caggiati | H. Yue | P. Nisticò | B. Palermo | H. Stabile | A. Gismondi | F. Silvestris | M. Ayyoub | R. Pinto | S. De Summa | M. Thurin | G. Masucci | J. Maleski | T. Bauer | M. Semeraro | F. Lehmann | R. Andtbacka | S. Spranger | Y. Yoshimoto | M. Capone | N. Mozzillo | A. Cohen | A. Anderson | L. Marra | A. Thompson | A. Anniciello | E. Cha | F. Mannavola | M. Tucci | S. Jégou | A. Cavalcanti | E. Wennerberg | B. Kwon | Alan E. Berger | S. Horváth | N. Richie | A. Passarelli | E. Patriarca | M. Capuano | M. Fierro | E. Marra | F. Capone | C. Jommi | E. Panaitescu | M. Kásler | N. Vimond | G. Aquino | L. Lattanzio | A. Olszanski | H. Hardy | F. Sabbatino | A. Caignard | A. Eggermont | V. Huber | M. Chacón | K. Bifulco | A. Tarhini | Tseng-Hui T Chen | J. Chou | Yang Wang | A. Ralabate | Á. Sávolt | S. D’Oronzo | P. Zeppa | M. De Tursi | C. Fortes | J. Wallin | C. Nigro | M. Ascierto | I. Poschke | Vincenzo Ingangi | K. Briscoe | A. Berrocal | N. Lendvai | Zhaojun Sun | A. Rivera | Yufan Zhao | D. Quaresmini | C. Fusciello | S. Voinea | V. Garrisi | J. Fourcade | I. Rooney | I. Caro | E. Caputo | Anna Ferretta | A. Marra | T. Balatoni | K. Éles | J. Olasz | E. Gambale | A. Stanciu | C. P. Prasad | R. Camerlingo | O. Alabiso | M. Occelli | I. Maida | G. Guida | L. Pan | R. Venhaus | P. De Cicco | C. Felici | J. Camarero | M. D. Di Cecilia | Sarah E. Nataraj | C. Botti | K. Pilones | R. Guarrasi | S. Coleman | F. Stephen Hodi | Xian He | V. Battarra | G. Ercolano | Mozzillo Nicola | Caracò Corrado | Marone Ugo | Yangyang Wang | F. Platini | A. Sponghini | C. Gause | G. Gentilcore | C. Blattner | A. Sandru | M. Gődény | M. Cerrone | F. Stratica | G. Bar-Sela | C. Robert | V. Faiola | A. D. Di Giacomo | Farnaz Moradi | F. Marino | C. Baldi | M. Davies | Roberta Miceli | F. Fratangelo | M. Patel | Lisa Chen | S. Strippoli | C. Cauchi | G. Di Monta | C. Carella | Hexiao Wang | A. Zappalà | Joel Jiang | Eugenio Fernandez | D. Koralek | B. Brady | A. Sancho | M. Ruisi | Concetta Ragone | Chiara Armogida | Maria Wolodarski | J. Larkin | Cindy Sanders | C. Harwood | H. Cho | E. Kalinka‐Warzocha | D. Rondonotti | Yangbo Fu | E. Farkas | Yago Pico de Coaña | C. D’Alterio | C. Vanpouille-Box | András Szollár | Antonio Doronzo | M. Nudo | Tucci Marco | S. Stefania | Speiser Daniel | Naoko Imai | I. Puzanov | M. Bolovan | Elisabetta Gambale | Rickard Linnskog | Camila Flores | V. Nanda | Giuseppe Cirin | Gerardo Bott | R. Gordan | Daniil Stoyakovskiy | Ryan Sullivan | David C. Smith | Lars Ny | Parneet Cheema | K. M. Eizmendi | Michaë la Semeraro | Passarelli Anna | Mannavola Francesco | Capone Mariaelena | M. Gabriele | Ascierto Paolo Antonio | Silvestris Franco | Christopher Borg | Anna Lisa De Presbiteris | Fabiola Gilda Cordaro | Rosaria Falcon | M. Carrier | Stefania Guida | Tiziana Cocco | Cosmo Di Donna | M. Foddai | P. Savoia | M. Di Marzo | Rosalie J. Russo | Giovanni Di Giulio | Alessandra Di Paolo | Fara De Murtas | V. Sorrentino | V. De Biasio | Theresa S. Pritchard | Farnaz Moradi | Mary M. Ruisi

[1]  A. Faje.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights , 2016, Pituitary.

[2]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[3]  S. Demaria,et al.  Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypothesis of Radiation , 2015 .

[4]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[5]  R. Kefford,et al.  Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series , 2015, Internal medicine journal.

[6]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[7]  F. Marincola,et al.  What’s new in melanoma? Combination! , 2015, Journal of Translational Medicine.

[8]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[9]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[10]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[12]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[13]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[14]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[15]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[16]  Jeffrey E. Lee,et al.  C-reactive protein as a marker of melanoma progression. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Tortora,et al.  Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? , 2015, Anti-cancer agents in medicinal chemistry.

[18]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[19]  J. Grob,et al.  Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. , 2015, European journal of endocrinology.

[20]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[21]  S. Demaria,et al.  Combination of radiotherapy and immune checkpoint inhibitors. , 2015, Seminars in radiation oncology.

[22]  M. Mandalà,et al.  PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[24]  D. Geynisman,et al.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review , 2014, Human vaccines & immunotherapeutics.

[25]  John Kirkwood,et al.  Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy , 2014, Melanoma research.

[26]  Hui Li,et al.  Long noncoding RNA HOTAIR involvement in cancer , 2014, Tumor Biology.

[27]  Josias H. Hamman,et al.  Review of Natural Compounds for Potential Skin Cancer Treatment , 2014, Molecules.

[28]  F. Fulciniti,et al.  SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression , 2014, Virchows Archiv.

[29]  S. Cinca,et al.  Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma , 2014, Journal of skin cancer.

[30]  S. Swetter,et al.  Fluorescence In Situ Hybridization Analysis of Atypical Melanocytic Proliferations and Melanoma in Young Patients , 2014, Pediatric dermatology.

[31]  David C. Smith,et al.  Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. , 2014 .

[32]  Pia Ragno,et al.  Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence , 2014, Oncotarget.

[33]  S. Rosenberg,et al.  Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? , 2014, Nature Reviews Clinical Oncology.

[34]  Y. Shoenfeld,et al.  IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist , 2014, Nature Reviews Immunology.

[35]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[36]  M. de Rosa,et al.  UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency , 2014, Molecular Cancer Therapeutics.

[37]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[38]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[39]  N. Soshnikova.  Hox genes regulation in vertebrates , 2014, Developmental dynamics : an official publication of the American Association of Anatomists.

[40]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[41]  A. Weaver,et al.  Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance , 2013, PloS one.

[42]  S. Corsello,et al.  Thyroid dysfunction as an unintended side effect of anticancer drugs. , 2013, Thyroid : official journal of the American Thyroid Association.

[43]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[44]  D. Rea,et al.  A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting , 2013, Molecular Cancer Therapeutics.

[45]  A. Papapetropoulos,et al.  Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer , 2013, Proceedings of the National Academy of Sciences.

[46]  F. Gonçalves,et al.  Cost-Effectiveness Of Ipilimumab In Previously Treated Patients For Advanced Melanoma In Portugal , 2013 .

[47]  W. Travis,et al.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Akers,et al.  Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies , 2013, Journal of Neuro-Oncology.

[49]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[50]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[51]  M. Atkins,et al.  Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis , 2013, Journal of medical economics.

[52]  G. Botti,et al.  Microenvironment and tumor progression of melanoma: New therapeutic prospectives , 2012, Journal of immunotoxicology.

[53]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[54]  S. Demaria,et al.  Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..

[55]  B. Jönsson,et al.  Cancer vaccines and immunotherapeutics , 2012, Human vaccines & immunotherapeutics.

[56]  S. Tyagi,et al.  Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. , 2012, American journal of physiology. Cell physiology.

[57]  A. Grossman,et al.  Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. , 2012, European journal of endocrinology.

[58]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[59]  F. Fulciniti,et al.  Increased HOX C13 expression in metastatic melanoma progression , 2012, Journal of Translational Medicine.

[60]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[61]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[62]  Myriam Gorospe,et al.  HuR function in disease. , 2012, Frontiers in bioscience.

[63]  N. Rajewsky,et al.  Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. , 2011, Molecular cell.

[64]  M. Stoppelli,et al.  The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. , 2011, Current pharmaceutical design.

[65]  H. V. van Boven,et al.  Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.

[66]  I. Niki,et al.  Hydrogen sulphide protects mouse pancreatic β‐cells from cell death induced by oxidative stress, but not by endoplasmic reticulum stress , 2011, British journal of pharmacology.

[67]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. McKeage,et al.  Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. , 2010, Journal of thoracic disease.

[69]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[70]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[71]  M. Mihm,et al.  The dermal-based borderline melanocytic tumor: a categorical approach. , 2010, Journal of the American Academy of Dermatology.

[72]  L. Zitvogel,et al.  Dendritic cell-derived exosomes for cancer immunotherapy: what's next? , 2010, Cancer research.

[73]  S. Jhanwar,et al.  Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization , 2010, Journal of cutaneous pathology.

[74]  P. Hersey,et al.  Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma , 2009, Cancer.

[75]  W. Filipowicz,et al.  Properties of the regulatory RNA-binding protein HuR and its role in controlling miRNA repression. , 2010, Advances in experimental medicine and biology.

[76]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  P. Butow,et al.  Evidence-based Dermatology: Study Psychological Responses and Coping Strategies among Patients with Malignant Melanoma a Systematic Review of the Literature for Editorial Comment See Page 1439 , 2022 .

[79]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[80]  A. Ribas,et al.  Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? , 2009, Clinical Cancer Research.

[81]  R. Franco,et al.  Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis , 2009, Molecular Cancer Therapeutics.

[82]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[83]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[84]  A. Enk,et al.  COX-2 expression in malignant melanoma: a novel prognostic marker? , 2009, Melanoma research.

[85]  M. Glassy,et al.  Antibody phage display: overview of a powerful technology that has quickly translated to the clinic. , 2009, Methods in molecular biology.

[86]  H. Lou,et al.  Diverse molecular functions of Hu proteins , 2008, Cellular and Molecular Life Sciences.

[87]  W. Weichert,et al.  Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. , 2008, International journal of oncology.

[88]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[89]  L. Fecher,et al.  Toward a molecular classification of melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  C. Berking,et al.  Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53 , 2007, Cell Death and Differentiation.

[91]  P. Moore,et al.  Hydrogen sulfide attenuates lipopolysaccharide‐induced inflammation by inhibition of p38 mitogen‐activated protein kinase in microglia , 2007, Journal of neurochemistry.

[92]  B. Scheithauer,et al.  Granulomatous adenohypophysitis after interferon and ribavirin therapy. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[93]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[94]  W. Weichert,et al.  Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2 , 2006, Modern Pathology.

[95]  E. Ridruejo,et al.  Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. , 2006, European journal of gastroenterology & hepatology.

[96]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[97]  C. Théry,et al.  Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. , 2005, Blood cells, molecules & diseases.

[98]  P. Grieco,et al.  Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide* , 2005, Journal of Biological Chemistry.

[99]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  F. Tas,et al.  Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma , 2004, American journal of clinical oncology.

[101]  C. Cockram,et al.  Panhypopituitarism in association with interferon-alpha treatment. , 2004, Singapore medical journal.

[102]  A. Heimann,et al.  Interferon-induced hypopituitarism. , 2003, The American journal of medicine.

[103]  Z. Battyáni,et al.  [Immuno-diagnosis of malignant melanoma]. , 2003, Magyar onkologia.

[104]  Ji Ming Wang,et al.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[105]  A. Shyu,et al.  RNA stabilization by the AU‐rich element binding protein, HuR, an ELAV protein , 1998, The EMBO journal.

[106]  W. Söllner,et al.  Need for supportive counselling--the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients. , 1998, Psychotherapy and psychosomatics.

[107]  W. Stolz,et al.  Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.

[108]  J. Steitz,et al.  Identification of HuR as a protein implicated in AUUUA‐mediated mRNA decay , 1997, The EMBO journal.

[109]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[110]  N. Sakane,et al.  Reversible hypopituitarism after interferonalfa therapy , 1995, The Lancet.

[111]  J. Nip,et al.  Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. , 1995, The Journal of clinical investigation.

[112]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[113]  Murray Turoff,et al.  The Delphi Method: Techniques and Applications , 1976 .